Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

KNSA

+ Watchlist+ Portfolio

Kiniksa Pharmaceuticals International, plc

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$95.11
52-Week Range
$37.02 – $99.31
Market Cap
$7.47B
P/E (TTM)
72.01
EPS (TTM)
1.32
Dividend Yield
0.00%
Advanced Metrics
Price/Book
10.50
PEG Ratio
—
Return on Equity
17.59%
Return on Assets
9.62%
Gross Margin
54.27%
Operating Margin
13.79%
Profit Margin
11.58%
Current Ratio
3.91
Debt/Equity
0.01
Total Debt
$7.88M
Free Cash Flow
$135.87M
Revenue Growth
58.10%
Earnings Growth
143.50%
Enterprise Value
$6.91B

Market Snapshot

About

Kiniksa Pharmaceuticals International, plc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with inflammatory and autoimmune diseases. The company's pipeline includes multiple programs targeting severe inflammatory conditions with significant unmet medical needs. Kiniksa leverages insights in immunology to develop novel treatments.